FBXW7 acts as an independent prognostic marker and inhibits tumor growth in human osteosarcoma.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 4346837)

Published in Int J Mol Sci on January 22, 2015

Authors

Zhanchun Li1, Jie Xiao2, Kongzu Hu3, Gang Wang4, Maoqiang Li5, Jidong Zhang6, Guangqi Cheng7

Author Affiliations

1: Department of Orthopaedic Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China. shrenji@gmail.com.
2: Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China. applexiaomz@gmail.com.
3: Department of Orthopaedic Surgery, the First Affiliated Hospital of Anhui Medical University, Anhui 230022, China. kongzhuhu@gmail.com.
4: Department of Orthopaedic Surgery, the Second Affiliated Hospital of Nanjing Medical University, Jiangsu 210029, China. kcb069js@gmail.com.
5: Department of Orthopaedic Surgery, Hangzhou First People's Hospital, Zhejiang 310006, China. maotai5488@gmail.com.
6: Department of Orthopaedic Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China. lzctgzyyx@gmail.com.
7: Department of Orthopaedic Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China. wly1618@gmail.com.

Articles cited by this

Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science (2001) 6.29

The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A (2004) 5.37

The epidemiology of osteosarcoma. Cancer Treat Res (2009) 5.10

FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79

FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science (2008) 3.78

SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69

The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science (2004) 2.83

SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol Cell Biol (2001) 2.56

The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell (2013) 2.24

New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol (2013) 1.97

BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 1.68

Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett (2012) 1.64

Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J Cancer (2010) 1.49

Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol (2012) 1.47

p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res (2009) 1.37

A phosphorylation cascade controls the degradation of active SREBP1. J Biol Chem (2009) 1.32

Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol Cancer (2014) 1.21

Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients. Cancer Sci (2010) 1.18

Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E. PLoS One (2013) 1.16

Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. Hepatol Res (2012) 1.15

c-Myc and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis. J Biol Chem (2008) 1.12

The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci (Landmark Ed) (2012) 1.12

C-Myc overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway. Oncol Res (2012) 0.91

Cyclin E1 is amplified and overexpressed in osteosarcoma. J Mol Diagn (2011) 0.91

hCDC4 variation in osteosarcoma. Cancer Genet Cytogenet (2006) 0.79